The objective of this project is to define the biochemical and biophysical mechanisms through which the selectins initiate rolling of leukocytes on the vessel wall under shear forces. Rolling is a prerequisite for stable adhesion and, ultimately, for emigration of leukocytes into the tissues in response to infection or injury. The work will focus on the interactions of P- and E-selectin, which are expressed on activated platelets and/or endothelial cells, with PSGL-l, a mucin- like glycoprotein expressed on leukocytes. We have shown that these interactions are critical for neutrophil rolling on P- or E-selectin. We have purified native or recombinant forms of PSGL-l and the selectins, and have developed monoclonal antibodies to each molecule. We will determine whether the consensus repeats and EGF domains of E and P- selectin affect their kinetics and affinities of binding to PSGL-l, and we will explore the structural basis for high affinity binding of Ca2+ to the lectin domains of the selectins. We will map the binding sites for mAbs and for the selectins on PSGL- 1, and seek to express a recombinant PSGL-1 that is glycosylated such its function resembles that of the native myeloid cell glycoprotein. We will examine the structural requirements for E- and P-selectin to mediate rolling of myeloid cells under shear stresses. Finally, we will examine the mechanical strength of binding of purified PSGL-1 incorporated into liposomes to P-selectin incorporated into planar membranes, under shear forces or using micromanipulation techniques. This project is closely linked with Project 4, where the structures of the glycans of PSGL-I will be determined. Within the context of the program project, this work is designed to extend our knowledge of protein-carbohydrate interactions, biomechanical factors affecting cell-cell adhesion under shear stress, and the recruitment of inflammatory cells to the vessel wall.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Program Projects (P01)
Project #
5P01HL054804-04
Application #
6110521
Study Section
Project Start
1998-08-01
Project End
1999-07-31
Budget Start
1997-10-01
Budget End
1998-09-30
Support Year
4
Fiscal Year
1998
Total Cost
Indirect Cost
Name
Oklahoma Medical Research Foundation
Department
Type
DUNS #
937727907
City
Oklahoma City
State
OK
Country
United States
Zip Code
73104
van Sluis, G L; Bruggemann, L W; Esmon, C T et al. (2011) Endogenous activated protein C is essential for immune-mediated cancer cell elimination from the circulation. Cancer Lett 306:106-10
Srivastava, Arvind; Wang, Jianfang; Majumder, Rinku et al. (2002) Localization of phosphatidylserine binding sites to structural domains of factor Xa. J Biol Chem 277:1855-63
Alberio, L; Lammle, B; Esmon, C T (2001) Protein C replacement in severe meningococcemia: rationale and clinical experience. Clin Infect Dis 32:1338-46
Liaw, P C; Mather, T; Oganesyan, N et al. (2001) Identification of the protein C/activated protein C binding sites on the endothelial cell protein C receptor. Implications for a novel mode of ligand recognition by a major histocompatibility complex class 1-type receptor. J Biol Chem 276:8364-70
Faust, S N; Levin, M; Harrison, O B et al. (2001) Dysfunction of endothelial protein C activation in severe meningococcal sepsis. N Engl J Med 345:408-16
Xu, J; Qu, D; Esmon, N L et al. (2000) Metalloproteolytic release of endothelial cell protein C receptor. J Biol Chem 275:6038-44
Gu, J M; Katsuura, Y; Ferrell, G L et al. (2000) Endotoxin and thrombin elevate rodent endothelial cell protein C receptor mRNA levels and increase receptor shedding in vivo. Blood 95:1687-93
Rezaie, A R; He, X (2000) Sodium binding site of factor Xa: role of sodium in the prothrombinase complex. Biochemistry 39:1817-25
Esmon, C T (2000) The anticoagulant and anti-inflammatory roles of the protein C anticoagulant pathway. J Autoimmun 15:113-6
Taylor Jr, F B; Stearns-Kurosawa, D J; Kurosawa, S et al. (2000) The endothelial cell protein C receptor aids in host defense against Escherichia coli sepsis. Blood 95:1680-6

Showing the most recent 10 out of 47 publications